TD Cowen Downgrades CRISPR Therapeutics (CRSP) to Underperform on lack of confidence in Casgevy launch
Tweet Send to a Friend
(Updated - December 11, 2023 6:19 AM EST)
TD Cowen analyst Tyler Van Buren downgraded CRISPR Therapeutics (NASDAQ: CRSP) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
TD Cowen analyst Tyler Van Buren downgraded CRISPR Therapeutics (NASDAQ: CRSP) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
